BioCentury | Apr 12, 2010
Financial News

PhytoMedical proposes follow-on

PhytoMedical Technologies Inc. (OTCBB:PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Date announced: 4/2/10 Type: Follow-on To be raised: Up to $2 million Price prior: $0.03 Note: The offering is not underwritten. Each unit comprises a share...
BioCentury | Mar 29, 2010
Company News

PhytoMedical management update

...N.J. Business: Endocrine, Nutraceuticals Hired: James Lynch as president and CEO, formerly a member of PhytoMedical's...
BioCentury | Aug 31, 2009
Clinical News

PMI-001: Phase IIb data

A completer analysis of 62 patients from a double-blind, active-controlled, U.S. Phase IIb trial showed that 60 mg PMI-001 thrice daily met the primary endpoint of an ACR20 response at 6 months compared with 1g...
BioCentury | Feb 9, 2009
Clinical News

PhytoMedical preclinical data

...In a mouse xenograft model of human glioblastoma, PhytoMedical's bis-intercalating bis-acridine compound significantly reduced tumor size...
...The company has rights to the compound from Dartmouth College (see BioCentury, Aug. 18, 2008). PhytoMedical Technologies Inc....
BioCentury | Aug 18, 2008
Company News

PhytoMedical, Dartmouth College deal

...cancer. The college will receive an undisclosed license fee and is eligible for milestone payments. Phytomedical...
...the compounds against difficult-to-treat cancer cells, including glioblastoma, colon cancer and small cell lung cancer. PhytoMedical Technologies Inc....
BioCentury | Apr 21, 2008
Company News

Phytomedics management update

Phytomedics Inc. , Jamesburg, N.J. Business: Autoimmune, Cancer, Nutraceuticals Hired: Laurie Smaldone Alsup as president and CEO, formerly VP of corporate strategy and issues management at Bristol-Myers Squibb Co. ; she replaces Bertold Fridlender, who will...
BioCentury | Jul 30, 2007
Company News

Phytomedics management update

Phytomedics Inc. , Jamesburg, N.J. Business: Autoimmune, Cancer, Nutraceuticals Hired: Arthur Finnel as CFO, formerly CFO of Wellgen Inc. WIR Staff autoimmune cancer...
BioCentury | Apr 2, 2007
Company News

PhytoMedical scientific advisory board update

PhytoMedical Technologies Inc. (PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Appointed: Mark Bossie, a former industry consultant WIR Staff...
BioCentury | Dec 4, 2006
Clinical News

PMI-001: Phase II data

In a 6-month, double-blind, U.S. Phase II trial in 121 patients, 53.3% of PMI-001 patients had an ACR20 response, the primary endpoint, compared with 21.3% of sulfasalazine-treated patients (p=0.0002). Responder rates for ACR50 (36.7% vs....
BioCentury | Oct 16, 2006
Company News

PhytoMedical scientific advisory board update

PhytoMedical Technologies Inc. (PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Appointed: Jay Wiggins, director of the medical development group at Schering AG’s Berlex Inc. subsidiary WIR Staff...
Items per page:
1 - 10 of 32
BioCentury | Apr 12, 2010
Financial News

PhytoMedical proposes follow-on

PhytoMedical Technologies Inc. (OTCBB:PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Date announced: 4/2/10 Type: Follow-on To be raised: Up to $2 million Price prior: $0.03 Note: The offering is not underwritten. Each unit comprises a share...
BioCentury | Mar 29, 2010
Company News

PhytoMedical management update

...N.J. Business: Endocrine, Nutraceuticals Hired: James Lynch as president and CEO, formerly a member of PhytoMedical's...
BioCentury | Aug 31, 2009
Clinical News

PMI-001: Phase IIb data

A completer analysis of 62 patients from a double-blind, active-controlled, U.S. Phase IIb trial showed that 60 mg PMI-001 thrice daily met the primary endpoint of an ACR20 response at 6 months compared with 1g...
BioCentury | Feb 9, 2009
Clinical News

PhytoMedical preclinical data

...In a mouse xenograft model of human glioblastoma, PhytoMedical's bis-intercalating bis-acridine compound significantly reduced tumor size...
...The company has rights to the compound from Dartmouth College (see BioCentury, Aug. 18, 2008). PhytoMedical Technologies Inc....
BioCentury | Aug 18, 2008
Company News

PhytoMedical, Dartmouth College deal

...cancer. The college will receive an undisclosed license fee and is eligible for milestone payments. Phytomedical...
...the compounds against difficult-to-treat cancer cells, including glioblastoma, colon cancer and small cell lung cancer. PhytoMedical Technologies Inc....
BioCentury | Apr 21, 2008
Company News

Phytomedics management update

Phytomedics Inc. , Jamesburg, N.J. Business: Autoimmune, Cancer, Nutraceuticals Hired: Laurie Smaldone Alsup as president and CEO, formerly VP of corporate strategy and issues management at Bristol-Myers Squibb Co. ; she replaces Bertold Fridlender, who will...
BioCentury | Jul 30, 2007
Company News

Phytomedics management update

Phytomedics Inc. , Jamesburg, N.J. Business: Autoimmune, Cancer, Nutraceuticals Hired: Arthur Finnel as CFO, formerly CFO of Wellgen Inc. WIR Staff autoimmune cancer...
BioCentury | Apr 2, 2007
Company News

PhytoMedical scientific advisory board update

PhytoMedical Technologies Inc. (PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Appointed: Mark Bossie, a former industry consultant WIR Staff...
BioCentury | Dec 4, 2006
Clinical News

PMI-001: Phase II data

In a 6-month, double-blind, U.S. Phase II trial in 121 patients, 53.3% of PMI-001 patients had an ACR20 response, the primary endpoint, compared with 21.3% of sulfasalazine-treated patients (p=0.0002). Responder rates for ACR50 (36.7% vs....
BioCentury | Oct 16, 2006
Company News

PhytoMedical scientific advisory board update

PhytoMedical Technologies Inc. (PYTO), Princeton, N.J. Business: Endocrine, Nutraceuticals Appointed: Jay Wiggins, director of the medical development group at Schering AG’s Berlex Inc. subsidiary WIR Staff...
Items per page:
1 - 10 of 32